Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
12 hrs ago | InvestorIdeas.com
July 11, 2014 The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall.
Trending on the Topix Network
17 hrs ago | Dissident Voice
Large corporate capitalism is a breed apart from smaller scale capitalism. The former can often avoid marketplace verdicts through corporate welfare, strip owner-shareholders of power over the top company bosses and offload the cost of their pollution, tax escapes and other "externalities" onto the backs of innocent people.
21 hrs ago | SiliconValley.com
Today: Yahoo picks up an Israeli video startup, Salesforce agrees to buy Palo Alto big-data startup RelateIQ for $390 million, and Microsoft scoops up a San Jose company.
23 hrs ago | Investor's Business Daily
The Nasdaq added 0.1% while the Dow Jones industrial average and S&P 500 each slipped 0.1%.
Yesterday | Reuters
Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.
France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.
Background : Gilead Sciences may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years.
Gilead is a cheap stock by any sort of fundamental earnings evaluation. According to Yahoo Finance , analysts expect the company to earn $6.35 per share in 2014 and $7.92 per share in 2015.
With stocks selling off and biotech giants like Gilead Sciences and Biogen Idec falling, Regeneron picked a heck of a day to deliver good news.
Since introduction of its new breakthrough drug Sovaldi, which comes close to "curing" Hepatitis C, Gilead has been under intense public scrutiny because the three-month course of therapy "is too expensive."
Market capitalization is an important data point for investors to keep an eye on, for various reasons.
Last month, the FDA took a much-anticipated step by issuing guidelines for drug makers that want to use social media, including examples of how to run paid search links on Google.
Temasek Holdings Pte is increasing investments in consumer, technology and health-care companies as Singapore's state-investment firm becomes less reliant on financial assets.
The nod was expected but important since Japan has a high rate of infection. This puts Bristol-Myers' Daklinza and Sunvepra regimen ahead of the HCV market leader, Gilead Sciences' Sovaldi, which has not yet been approved in Japan, although it's following close behind.
Gilead does an excellent job of maintaining ownership over its active drug ingredients, and this creates cash cows that add significant contributions to cash flow per share figures.
Updated: Fri Jul 11, 2014 11:15 pm
Copyright © 2014 Topix LLC